Delcath Systems Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma

Reuters

2025/10/19

<a href="https://laohu8.com/S/DCTH">Delcath Systems</a> Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma

Delcath Systems, Inc. has announced the results of the CHOPIN randomized Phase 2 clinical trial, which were presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. The trial met its primary endpoint and investigated the combination of percutaneous hepatic perfusion (PHP) and immune checkpoint inhibitor (ICI) therapy in patients with metastatic uveal melanoma. Delcath will host a conference call and webcast on October 20, 2025, at 8:45 a.m. Eastern Time to discuss the CHOPIN Trial results, as well as provide an overview of financial results and company guidance. A replay of the webinar will be available on the company's website following the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251018759712) on October 18, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576041383"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576041383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576041383?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-19 04:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576041383","market":"nz","top_or_hot":-1,"title":"Delcath Systems Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Delcath Systems, Inc. has announced the results of the CHOPIN randomized Phase 2 clinical trial, which were presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. The trial met its primary endpoint and investigated the combination of percutaneous hepatic perfusion (PHP) and immune checkpoint inhibitor (ICI) therapy in patients with metastatic uveal melanoma. Delcath will host a conference call and webcast on October 20, 2025, at 8:45 a.m. Eastern Time to discuss the CHOPIN Trial results, as well as provide an overview of financial results and company guidance. A replay of the webinar will be available on the company's website following the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251018759712) on October 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delcath Systems Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelcath Systems Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-19 04:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Delcath Systems, Inc. has announced the results of the CHOPIN randomized Phase 2 clinical trial, which were presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. The trial met its primary endpoint and investigated the combination of percutaneous hepatic perfusion (PHP) and immune checkpoint inhibitor (ICI) therapy in patients with metastatic uveal melanoma. Delcath will host a conference call and webcast on October 20, 2025, at 8:45 a.m. Eastern Time to discuss the CHOPIN Trial results, as well as provide an overview of financial results and company guidance. A replay of the webinar will be available on the company's website following the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251018759712) on October 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCTH","symbol_name":"迪卡斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251018:nNDLb8qMWF:1","article_id":"2576041383","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576041383","pubTimestamp":1760818403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Delcath Systems, Inc. has announced the results of the CHOPIN randomized Phase 2 clinical trial, which were presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, at the 2025 European Society of Medical Oncology  Annual Congress. The trial met its primary endpoint and investigated the combination of percutaneous hepatic perfusion  and immune checkpoint inhibitor  therapy in patients with metastatic uveal melanoma. Delcath will host a conference call and webcast on October 20, 2025, at 8:45 a.m. Eastern Time to discuss the CHOPIN Trial results, as well as provide an overview of financial results and company guidance. A replay of the webinar will be available on the company's website following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCTH":"迪卡斯","BK4082":"医疗保健设备"},"translate_title":"Delcath Systems报告CHOPIN 2期试验达到转移性葡萄膜黑色素瘤的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCTH":0.9},"content_text":"Delcath Systems Reports CHOPIN Phase 2 Trial Meets Primary Endpoint in Metastatic Uveal Melanoma\n    \n\n        Delcath Systems, Inc. has announced the results of the CHOPIN randomized Phase 2 clinical trial, which were presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. The trial met its primary endpoint and investigated the combination of percutaneous hepatic perfusion (PHP) and immune checkpoint inhibitor (ICI) therapy in patients with metastatic uveal melanoma. Delcath will host a conference call and webcast on October 20, 2025, at 8:45 a.m. Eastern Time to discuss the CHOPIN Trial results, as well as provide an overview of financial results and company guidance. A replay of the webinar will be available on the company's website following the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251018759712) on October 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}